GLP-1 drugs are FDA-approved for patients with obesity, those who are overweight with related health conditions and those with specific health issues
Clinical studies have shown that weight regain can occur after stopping semaglutide or tirzepatide, along with some reversal of cardiometabolic improvements
Future studies of people treated with these drugs for obesity, without accompanying diabetes, are awaited with interest
Why the research doesn't support stopping and starting It's also worth noting that current clinical consensus and available evidence doesnt support using GLP-1 medications as a short-term fix - something to use to lose weight quickly, stop, and restart later if the weight comes back
Medications known as glucagon-like peptide-1 receptor (GLP-1) agonists continue to rise in popularity thanks to their ability to help manage blood sugar levels and reduce hunger and food intake, thus potentially supporting weight loss
M.MillerL